8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jan 28, 2008)

Filed January 28, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on January 23, 2008, significant positive top-line results from its Phase II GEMINI study for ALN-RSV01. This experimental RNAi therapeutic is being developed for the treatment of Respiratory Syncytial Virus (RSV) infection. The study demonstrated that ALN-RSV01 was both safe and well-tolerated by adult subjects, which is a critical factor for any therapeutic. More importantly for investors, the study showed statistically significant anti-viral activity. While the full results are slated for presentation at an upcoming symposium, these initial findings suggest ALN-RSV01 has the potential to effectively combat RSV infection. This positive development is a key indicator of the drug candidate's progress through clinical trials and strengthens Alnylam's pipeline.

Key Highlights

  • 1Alnylam Pharmaceuticals announced positive top-line results for its Phase II ALN-RSV01 study (GEMINI) on January 23, 2008.
  • 2ALN-RSV01 is an RNAi therapeutic targeting Respiratory Syncytial Virus (RSV) infection.
  • 3The GEMINI study demonstrated that ALN-RSV01 was safe and well-tolerated in adult subjects.
  • 4Statistically significant anti-viral activity was observed with ALN-RSV01.
  • 5The study was a double-blind, placebo-controlled, randomized trial involving 88 adult subjects.
  • 6ALN-RSV01 was administered intranasally over five consecutive days.
  • 7Complete study results will be presented at the International Symposium on Respiratory Viral Infections in early March 2008.

Frequently Asked Questions

ALN-RSV01 is an investigational RNAi therapeutic developed by Alnylam Pharmaceuticals for the treatment of Respiratory Syncytial Virus (RSV) infection.

The study reported positive top-line results, indicating that ALN-RSV01 was safe and well-tolerated. Crucially, it also demonstrated statistically significant anti-viral activity against RSV.

This finding suggests that the drug is not only safe but also has a measurable and meaningful effect on the virus, increasing the probability of its eventual success as a treatment and its potential commercial value.

The complete results of the GEMINI study are scheduled to be presented at the International Symposium on Respiratory Viral Infections, taking place from February 28 to March 2, 2008.